PPAR-δ is repressed in Huntington's disease, is required for normal neuronal function and can be targeted therapeutically.

Loading...
Thumbnail Image

Date

2016-01

Authors

Dickey, Audrey S
Pineda, Victor V
Tsunemi, Taiji
Liu, Patrick P
Miranda, Helen C
Gilmore-Hall, Stephen K
Lomas, Nicole
Sampat, Kunal R
Buttgereit, Anne
Torres, Mark-Joseph Manalang

Journal Title

Journal ISSN

Volume Title

Repository Usage Stats

142
views
144
downloads

Citation Stats

Abstract

Huntington's disease (HD) is a progressive neurodegenerative disorder caused by a CAG trinucleotide repeat expansion in the huntingtin (HTT) gene, which encodes a polyglutamine tract in the HTT protein. We found that peroxisome proliferator-activated receptor delta (PPAR-δ) interacts with HTT and that mutant HTT represses PPAR-δ-mediated transactivation. Increased PPAR-δ transactivation ameliorated mitochondrial dysfunction and improved cell survival of neurons from mouse models of HD. Expression of dominant-negative PPAR-δ in the central nervous system of mice was sufficient to induce motor dysfunction, neurodegeneration, mitochondrial abnormalities and transcriptional alterations that recapitulated HD-like phenotypes. Expression of dominant-negative PPAR-δ specifically in the striatum of medium spiny neurons in mice yielded HD-like motor phenotypes, accompanied by striatal neuron loss. In mouse models of HD, pharmacologic activation of PPAR-δ using the agonist KD3010 improved motor function, reduced neurodegeneration and increased survival. PPAR-δ activation also reduced HTT-induced neurotoxicity in vitro and in medium spiny-like neurons generated from stem cells derived from individuals with HD, indicating that PPAR-δ activation may be beneficial in HD and related disorders.

Department

Description

Provenance

Citation

Published Version (Please cite this version)

10.1038/nm.4003

Publication Info

Dickey, Audrey S, Victor V Pineda, Taiji Tsunemi, Patrick P Liu, Helen C Miranda, Stephen K Gilmore-Hall, Nicole Lomas, Kunal R Sampat, et al. (2016). PPAR-δ is repressed in Huntington's disease, is required for normal neuronal function and can be targeted therapeutically. Nat Med, 22(1). pp. 37–45. 10.1038/nm.4003 Retrieved from https://hdl.handle.net/10161/15677.

This is constructed from limited available data and may be imprecise. To cite this article, please review & use the official citation provided by the journal.


Unless otherwise indicated, scholarly articles published by Duke faculty members are made available here with a CC-BY-NC (Creative Commons Attribution Non-Commercial) license, as enabled by the Duke Open Access Policy. If you wish to use the materials in ways not already permitted under CC-BY-NC, please consult the copyright owner. Other materials are made available here through the author’s grant of a non-exclusive license to make their work openly accessible.